NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
Clinical Trials
3 trialsNCT01810913 2026-03-13
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT02635009 2026-03-02
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer
NRG Oncology
Phase 2/3 Completed